CHI 907
Alternative Names: CHI-907Latest Information Update: 27 Jul 2022
At a glance
- Originator Canopy Health Innovations
- Class Anxiolytics; Cannabinoids
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 27 Jul 2022 No development reported - Phase-II for Anxiety disorders (In volunteers) in USA (unspecified route)
- 01 Jun 2021 Canopy Health Innovations terminates a phase II trial in Anxiety (In volunteers) in USA (unspecified route) (due to COVID-2019-related recruitment challenges) (NCT04269252)
- 03 Feb 2020 Phase-II clinical trials in Anxiety disorders (In volunteers) in USA (unspecified route) (NCT04269252)